EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase II)Open Access · CC BY 4.0

Improvement in neuropsychological function with memantine treatment among patients with systemic lupus erythematosus: a phase 2 randomised placebo-controlled clinical trial

Jillian P Rhoads, Lillian N Ahmad, Jonathan Williams, Liping Du, Emily A Littlejohn, Meera G Subash, Jana K Shirey-Rice, Jill M Pulley, Wesley H Self, Erin M Collar, Narender Annapureddy, April Barnado und 2 weitere

Annals of the Rheumatic Diseases · 2026-11 · 85 (11) · 2183-2193

DOI: 10.1016/j.ard.2026.07.015 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Annals of the Rheumatic Diseases, 2026-11. Verfasst von Jillian P Rhoads und 13 weiteren Autor:innen. Beteiligte Einrichtung: Vanderbilt Institute of Clinical and Translational Research, Vanderbilt Health, Nashville, Tennessee, USA. Electronic address: jillian.p.rhoads.1@vum…. Hauptthemen laut MEDLINE: Memantine, Lupus Erythematosus, Systemic, Excitatory Amino Acid Antagonists. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Robert J Kleberg Jr & Helen C Kleberg Foundation, National Center for Advancing Translational Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: Neuropsychological symptoms are common, disabling manifestations of systemic lupus erythematosus (SLE) that can persist despite immunomodulatory treatment. We evaluated whether the N-methyl-D-aspartate receptor (NMDAR) antagonist, memantine, improves cognitive function in individuals with SLE and neuropsychological dysfunction. METHODS: ClearMEMory (NCT03527472) was a multisite, randomised, placebo-controlled 12-week clinical trial of memantine titrated to 40 mg/d among adults with SLE with objective neuropsychological dysfunction. The primary outcome was change in the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) total score from baseline to week 12. Additional outcomes included change in RBANS total score above a threshold considered clinically important (score increase ≥8) and patient global impression of change (PGI-C). RESULTS: Of 131 patients screened, 56 were randomised, and 43 completed primary outcome assessment and were analysed, including 18 in the memantine group and 25 in the placebo group. Improvement in RBANS total score between baseline and week 12 was greater in the memantine group (median change: +8) than the placebo group (median change: +5) (P = .032); 12 (66.7%) participants in the memantine group and 9 (36.0%) participants in the placebo group had an increase in total RBANS score ≥8 (P = .047) (number-needed-to-treat = 3.3). Using the PGI-C, 61% of participants in the memantine group and 36% of participants in the placebo group self-reported improvement (P = .19). Discontinuation due to adverse events occurred in 5 (19%) participants in the memantine group and 5 (17%) participants in the placebo group. CONCLUSIONS: Among patients with SLE-associated neuropsychological dysfunction, treatment with memantine for 12 weeks improved objective neuropsychological function.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MemantineLupus Erythematosus, SystemicExcitatory Amino Acid AntagonistsHumansFemaleMaleAdultMiddle AgedNeuropsychological TestsTreatment OutcomeDouble-Blind MethodReceptors, N-Methyl-D-AspartateCognitive Enhancement

Substanzen

MemantineExcitatory Amino Acid AntagonistsReceptors, N-Methyl-D-Aspartate

Autor:innen und Institutionen

  • Vanderbilt Institute of Clinical and Translational Research, Vanderbilt Health, Nashville, Tennessee, USA. Electronic address: jillian.p.rhoads.1@vumc.org.
  • Vanderbilt Institute of Clinical and Translational Research, Vanderbilt Health, Nashville, Tennessee, USA.
  • Division of Rheumatology and Immunology, Department of Medicine, Vanderbilt Health, Nashville, Tennessee, USA.
  • Department of Biostatistics, Vanderbilt Health, Nashville, Tennessee, USA.
  • Department of Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, Ohio, USA.
  • Division of Rheumatology, McGovern Medical School, UTHealth Houston, Houston, Texas, USA.

Förderung

  • Robert J Kleberg Jr & Helen C Kleberg Foundation
  • National Center for Advancing Translational Sciences

Zitieren

APA

Rhoads, J. P., Ahmad, L. N., Williams, J., Du, L., Littlejohn, E. A., Subash, M. G., Shirey-Rice, J. K., Pulley, J. M., Self, W. H., Collar, E. M., Annapureddy, N., Barnado, A., Jackson, J. C., & Crofford, L. J. (2026). Improvement in neuropsychological function with memantine treatment among patients with systemic lupus erythematosus: a phase 2 randomised placebo-controlled clinical trial. Annals of the Rheumatic Diseases, 85(11), 2183-2193. https://doi.org/10.1016/j.ard.2026.07.015

Vancouver

Rhoads JP, Ahmad LN, Williams J, Du L, Littlejohn EA, Subash MG, et al. Improvement in neuropsychological function with memantine treatment among patients with systemic lupus erythematosus: a phase 2 randomised placebo-controlled clinical trial. Annals of the Rheumatic Diseases. 2026;85(11):2183-2193. doi:10.1016/j.ard.2026.07.015

BibTeX
@article{Rhoads2026,
  author = {Rhoads, Jillian P and Ahmad, Lillian N and Williams, Jonathan and Du, Liping and Littlejohn, Emily A and Subash, Meera G and Shirey-Rice, Jana K and Pulley, Jill M and Self, Wesley H and Collar, Erin M and Annapureddy, Narender and Barnado, April and Jackson, James C and Crofford, Leslie J},
  title = {Improvement in neuropsychological function with memantine treatment among patients with systemic lupus erythematosus: a phase 2 randomised placebo-controlled clinical trial},
  journal = {Annals of the Rheumatic Diseases},
  year = {2026},
  volume = {85},
  number = {11},
  pages = {2183--2193},
  doi = {10.1016/j.ard.2026.07.015}
}
Kostenlos starten →